Revolution Medicines Stock Quote RVMD - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

39.56

Bid

37.90

Ask

39.57

Volume

1,439,659

37.09 Day's Range 39.49

15.4401 52 Week Range 39.49

Market Cap

60.935M

Previous Close

37.28

Open

37.24

Last Trade

39.57

Last Trade Time

Financial Volume

$ 54,287,350

VWAP

37.7085

Average Volume (3m)

1,507,829

Shares Outstanding

164,690,408

Dividend Yield

PE Ratio

-0.14

Earnings Per Share (EPS)

-2.65

Revenue

11.58M

Net Profit

-436.37M

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products include R... Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products include RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.revmed.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Revolution Medicines Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker RVMD. The last closing price for Revolution Medicines was $37.28. Over the last year, Revolution Medicines shares have traded in a share price range of $ 15.4401 to $ 39.49.

Revolution Medicines currently has 164,690,408 shares outstanding. The market capitalization of Revolution Medicines is $60.94 million. Revolution Medicines has a price to earnings ratio (PE ratio) of -0.14.

Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024

REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...

Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

REDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...

Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

Two original papers in Nature highlight the discovery and translational implications of RMC-7977, a RAS(ON) multi-selective tri-complex inhibitor that exhibits unprecedented anti-tumor activity in...

Revolution Medicines to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...

Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024

REDWOOD CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...

Form 4 - Statement of changes in beneficial ownership of securities

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	3.28	9.0407938258	36.28	39.49	34.65	1204087	36.23499032	CS
4	8.92	29.1122715405	30.64	39.49	29.74	1415709	35.38887049	CS
12	9.78	32.8408327737	29.78	39.49	28.43	1507829	32.42378047	CS
26	19.75	99.6971226653	19.81	39.49	18.79	1495526	28.50144162	CS
52	16.22	69.4944301628	23.34	39.49	15.4401	1570382	27.52833575	CS
156	5.72	16.9030732861	33.84	39.49	14.08	1052926	25.74465051	CS
260	10.21	34.7870528109	29.35	56.18	14.08	875273	27.33249559	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
CTMXCytomX Therapeutics Inc	$ 5.14 (215.34%)	206.72M
SYTSYLA Technologies Company Ltd	$ 3.375 (131.16%)	12.12M
RGFReal Good Food Company Inc	$ 0.49 (72.78%)	4.67M
BCABBioAtla Inc	$ 3.39 (50.33%)	4.1M
PBMPsyence Biomedical Ltd	$ 1.2099 (34.52%)	5.86M
CETXCemtrex Inc	$ 0.3055 (-73.20%)	18.61M
BENFBeneficient	$ 2.041 (-38.52%)	292.68k
CVRXCVRx Inc	$ 10.075 (-35.04%)	1.58M
CRMLCritical Metals Corporation	$ 7.96 (-24.19%)	27k
CGCCanopy Growth Corporation	$ 11.4352 (-23.15%)	55.26M
SQQQProShares UltraPro Short QQQ	$ 12.22 (2.26%)	210.88M
CTMXCytomX Therapeutics Inc	$ 5.14 (215.34%)	206.72M
AKANAkanda Corporation	$ 0.1149 (23.55%)	181.14M
TQQQProShares UltraPro QQQ	$ 51.60 (-2.15%)	104.3M
AMZNAmazon.com Inc	$ 179.00 (2.29%)	95.02M